| Name | Title | Contact Details |
|---|
Abon Pharmaceuticals is a Northvale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headquartered in Louisville, Kentucky, with nearly $2 billion in annual revenues, PharMerica is one of the largest and fastest growing institutional pharmacy companies in America. We are a premier pharmacy services provider dedicated to providing innovative solutions for customers and patients. At PharMerica, you can choose your career path – hospital pharmacy, long term care pharmacy, corporate and non-clinical opportunities. We employ some of the industry`s best and brightest innovators and clinicians. With more than 100 long-term care pharmacies in over 45 states nationwide, PharMerica employs approximately 5,500 dedicated employees and pharmacy professionals. We offer our staff the opportunity to learn the business and cross train in other areas to provide a catalyst for their career growth within PharMerica. We also recruit our next generation of leaders by hiring new graduates from some of the nation`s top pharmacy and business schools. In addition, we offer educational opportunities through internships and our management training program. As a fast growing organization, we can provide you with the opportunity to kick start your career or advance your skills using some of the industry`s state-of-the-art technology. We foster an environment that encourages our high performers. Because we are a national company, we can provide opportunities for employees that desire to relocate. In addition, we offer a comprehensive benefits package that supports your quality of life.
Imprimis Pharmaceuticals is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at affordable prices. We are pioneering a new commercial pathway in the pharmaceutical industry, using compounding pharmacies for the formulation and distribution of high quality, proprietary formulations that are supported by the clinical experience of physicians and their patients. We are focused on ophthalmology and urology drug therapies; however we also sell other formulations outside of our core ophthalmology and urology therapeutic areas. All of our innovative drug formulations are born from the clinical experience of physician prescribers and pharmacist formulators. We believe our unique business model provides us with the opportunity to address unmet patient needs while delivering safe, near-term and affordable medical solutions to Americans. We have made tremendous progress since the launch of our ophthalmology business and our Go Dropless™ educational campaign in April 2014. Our ophthalmology business is disrupting the billion dollar eye drop market as physicians are adopting Dropless Therapy™ for their patients. We recently announced the availability of our LessDrops™ proprietary topical combination eye drops for post LASIK and other ocular surgeries. During first quarter 2015, we launched our urology business, entering the multi-billion dollar interstitial cystitis (IC) market. In connection with our urology launch, we will commercialize our patented Hep-Lido-A formulation and promote the Defeat IC™ educational campaign focused on medical practitioners and the estimated ten million women and men in the U.S. chronically affected by IC and PBS. We are committed to customer relations, highest quality standards, accessible innovation and solving the unmet needs in the markets we serve. We are delivering on the promise of our unique model and look forward to continuing to serve the needs of our customers with additional novel drug therapies in our product portfolio, and in turn grow our business. Our hope is that through the success of our business we will reduce healthcare costs and provide Americans access to high quality, novel and previously unavailable medicines.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company`s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting autoimmune and inflammatory diseases and central nervous systems (CNS) disorders.
Strategic Behavioral Health is a national mental health facility offering inpatient & outpatient treatment programs. We help families put their lives back together.